VIRX Insider Trading
Insider Ownership Percentage: 10.69%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Viracta Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Viracta Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Viracta Therapeutics Share Price & Price History
Current Price: $0.03
Price Change: ▲ Price Increase of +0.0066 (32.67%)
As of 04/3/2025 04:59 PM ET
Viracta Therapeutics Insider Trading History
Viracta Therapeutics Institutional Trading History
Data available starting January 2016
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Read More on Viracta Therapeutics
Volume
222,755 shs
Average Volume
1,072,115 shs
Market Capitalization
$1.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44
Who are the company insiders with the largest holdings of Viracta Therapeutics?